BR Lewis Pharmaceuticals

BR Lewis Pharmaceuticals was a United Kingdom-based pharmaceutical wholesaler and parallel importer specializing in the importation, repackaging, and distribution of branded medicines from the European Union. A subsidiary of the Doncaster Pharmaceuticals Group, the company held numerous licenses for the parallel distribution of high-volume products such as Aprovel (irbesartan), Crestor (rosuvastatin), and Abilify (aripiprazole). In May 2022, its parent company entered administration, and in August 2022, the Dutch BModesto Group acquired the assets and licenses of BR Lewis Pharmaceuticals, integrating them into the newly formed Doncaster Pharma Limited.